Cipla Ltd Corporate Actions

Cipla forays into weight management segment in India

 Copy Link

At around 1.51 PM, Cipla was trading almost flat at ₹1,485.40 per piece, against the previous close of ₹1,485 on NSE.

Cipla Receives One Observation in USFDA Inspection at Bengaluru Plant

 Copy Link

At the end of the inspection, the US FDA issued a Form 483 with one observation which was received at the conclusion of the inspection during the closing meeting.

Cipla Q4 Profit Surges 30% to ₹1,214 Crore

 Copy Link

The EBITDA margin saw a considerable improvement, moving up 184 basis points to 22.84%, from 21% in Q4 FY23.

Cipla Gets USFDA Nod for Cancer Drug Paclitaxel

 Copy Link

For the quarter, net profit soared 49% on-year to ₹1,570 crore, on the back of higher revenue and better operating efficiency.

Cipla Secures USFDA Nod for Nilotinib, Set for 2025-26 Launch

 Copy Link

According to Cipla, the regulatory clearance serves as an important landmark in the Company's journey, allowing it to expand the depth of its oncology portfolio and its foothold in the US market

Cipla's Bengaluru Plant Gets USFDA VAI Status

 Copy Link

The VAI status indicates that there are no such complying issues with the facility; hence, the USFDA will not take any regulatory or administrative action against the facility.

Cipla Q3 Profit Jumps 49%, Revenue Up 7%

 Copy Link

For the first nine months of FY25, Cipla's EBITDA margin stood at 26.9%, already above its full-year guidance of 24.5% to 25.5%.

Cipla Promoters Set to Offload ₹2,000 Crore Stake via Block Deals

 Copy Link

Cipla reported a net profit of ₹1,303 crore, marking a 15% increase compared to the same period last year.

Cipla zooms ~10% as USFDA classifies Goa facility as VAI

 Copy Link

The VAI designation now clears the way for significant specialised launches, such as the Abraxane generic.

Cipla Shares Surge 10% on USFDA News

 Copy Link

The company is now able to pursue important speciality medicine launches because to its VAI classification.